AC
CNTA

Armistice Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Armistice Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500,000
Closed -$12.5M – 306
2025
Q4 		$12.5M Buy
500,000
+122,000
+32% +$3.09M 0.15% 93
2025
Q3 		$9.17M Sell
378,000
-22,000
-6% -$391K 0.14% 89
2025
Q2 		$5.26M Sell
400,000
-68,000
-15% -$862K 0.09% 97
2025
Q1 		$6.73M Buy
+468,000
New +$7.66M 0.1% 105

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Armistice Capital's CNTA Position: Q1 2026 in Review

Armistice Capital sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 500,000 shares — an estimated $12.5M sold.

Armistice Capital first reported a position in CNTA in Q1 2025 and held it in 4 quarters. The position peaked at $12.5M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Armistice Capital reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Armistice Capital sold 500,000 Centessa Pharmaceuticals shares in Q1 2026, an estimated $12.5M.
  • Armistice Capital first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 4 quarters.
  • Armistice Capital's Centessa Pharmaceuticals position peaked at $12.5M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.